Peter Diamandis on longevity escape velocity, AI-driven scientific breakthroughs, and why he's investing more in energy than AI

Peter Diamandis on longevity escape velocity, AI-driven science, and energy investment

Peter Diamandis, executive chairman of XPRIZE, argues the next decade will produce a golden era of scientific discovery — not because researchers got smarter, but because AI has multiplied the number of effective geniuses working on hard problems by what he describes as a billion-fold. His near-term focus is less on LLM revenue and more on what happens when those systems crack physics, chemistry, and biology.

AI and scientific breakthroughs

The commercial story most investors are telling about frontier AI labs centers on recurring model revenue. Diamandis thinks that misses the bigger prize. The real value, in his view, comes from the breakthroughs those models enable — and the question he poses directly is what solving longevity would actually be worth.

Kevin Weil, now head of science at OpenAI after serving as its chief product officer, appeared at Diamandis's Abundance Summit this year. The role itself signals a strategic shift: OpenAI is deploying its models on physics problems, not just language tasks. Diamandis co-authored a paper with Alex Wissner-Gross of Eoghan Systems titled Solve Everything, arguing that after effectively solving math, AI systems are moving into physics, chemistry, material science, and biology in sequence.

“These AGIs and ASI systems are going to solve math — what comes next is physics and chemistry, biology, material sciences... I'm investing more in energy companies than I am in AI companies these days, because how fundamental it is... Rick Kurzweil talks about longevity escape velocity by 2033 — for every year that you're alive, science extends your life for greater than a year.”

Longevity

Diamandis spends roughly half his time on longevity investing and company building. He frames GLP-1s as the first true longevity drug, because metabolic health and visceral fat load are direct determinants of lifespan. Later-generation GLP-1 compounds now in development aim to preserve muscle mass, which earlier versions did not.

The more significant near-term development, in his telling, is David Sinclair's OSK trial at Life Biosciences, in which Diamandis is an investor and advisor. The trial applies three of the four Yamanaka factors to reverse cellular age. It progressed from mice to primates and entered human trials this month, initially targeting macular degeneration and nystagmus. Because the mechanism targets cellular age rather than a specific tissue, Sinclair's hypothesis is that it will generalize to all organs.

XPRIZE is running a $101 million HealthSpan prize — set at that figure specifically because the sponsor wanted to exceed Elon Musk's $100 million carbon capture prize — asking teams to deliver a longevity therapy within a year that reverses functional age by 20 years across cognition, muscle, and immune function. Over 700 teams are competing, with a winner expected by 2030.

Ray Kurzweil's prediction of longevity escape velocity by 2033 is the goalpost Diamandis returns to — the point at which science extends life by more than one year for every year lived. Sam Altman and Brian Armstrong are both backing separate longevity ventures working toward age reversal.

Energy over AI

Diamandis says he is currently investing more in energy companies than AI companies. His reasoning is structural: chips were the gating factor for AI, and they no longer are. Energy is. That shift makes energy the more fundamental bet.

On nuclear, he argues the public narrative is stuck on first- and second-generation fission, referencing Fukushima and Three Mile Island, while the new generation of small modular reactors and fusion plants carries a materially different safety profile. He says he would put a nuclear power source in his backyard. His practical transition thesis is that existing coal plants — which already have permitting, supply chains, and grid connections — become the natural chassis for next-generation nuclear, replacing the combustion component while keeping the infrastructure.

The XPRIZE desalination competition, its largest active prize at $119 million, is funded by the president of Abu Dhabi and targets energy efficiency gains and reduced environmental impact from brine discharge. Diamandis also points to atmospheric water capture as a parallel track, noting that quadrillions of liters of water exist in the atmosphere and that extraction technology is becoming viable at scale.

Narrative and the Future Vision XPRIZE

Diamandis launched the Future Vision XPRIZE a month ago, partnering with Mark Benioff at Salesforce, Google, Cathie Wood at ARK Invest, and Rod Roddenberry, son of the Star Trek creator. Teams submit three-minute trailers depicting hopeful futures; the winner's film gets made. The motivation is explicit: he believes Hollywood's predominantly dystopian output — Ex Machina, Terminator, Black Mirror — is generating fear about AI and technology that makes people less capable of engaging productively with what is coming. Star Trek, he says, is the model he wants to recreate.

His new book, We Are the Gods: A Survival Guide to the Age of Abundance, publishes the day after this conversation. It follows his 2012 book Abundance and centers on the mindset shift required to treat AI as something happening for you rather than to you.

Key figures to watch: David Sinclair's OSK human trial results, the XPRIZE HealthSpan winner by 2030, and where energy investment allocations from tech-adjacent investors move as the chip constraint gives way to a power constraint.